Janus Henderson Group PLC Purchases 880,505 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Janus Henderson Group PLC boosted its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 14.5% in the first quarter, Holdings Channel reports. The fund owned 6,945,813 shares of the company’s stock after acquiring an additional 880,505 shares during the period. Janus Henderson Group PLC owned 0.11% of Mirum Pharmaceuticals worth $641,764,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of MIRM. ADAR1 Capital Management LLC acquired a new stake in shares of Mirum Pharmaceuticals in the first quarter valued at about $573,000. California State Teachers Retirement System lifted its position in shares of Mirum Pharmaceuticals by 22.1% during the 1st quarter. California State Teachers Retirement System now owns 44,476 shares of the company’s stock worth $4,109,000 after purchasing an additional 8,065 shares during the last quarter. Rock Springs Capital Management LP boosted its stake in Mirum Pharmaceuticals by 6.4% during the 1st quarter. Rock Springs Capital Management LP now owns 811,294 shares of the company’s stock valued at $74,947,000 after purchasing an additional 49,000 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Mirum Pharmaceuticals by 63.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 55,693 shares of the company’s stock valued at $5,145,000 after purchasing an additional 21,579 shares during the period. Finally, Quantinno Capital Management LP grew its holdings in Mirum Pharmaceuticals by 166.2% in the 1st quarter. Quantinno Capital Management LP now owns 8,497 shares of the company’s stock valued at $785,000 after buying an additional 5,305 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages have commented on MIRM. Wolfe Research began coverage on Mirum Pharmaceuticals in a research report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price target on the stock. Weiss Ratings cut Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, June 23rd. Citizens Jmp raised their price objective on shares of Mirum Pharmaceuticals from $140.00 to $146.00 and gave the stock a “market outperform” rating in a research note on Monday, June 15th. Robert W. Baird boosted their target price on shares of Mirum Pharmaceuticals from $112.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Finally, HC Wainwright reiterated a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $143.40.

Insider Activity

In related news, CEO Christopher Peetz sold 20,000 shares of the company’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $122.27, for a total value of $2,445,400.00. Following the completion of the transaction, the chief executive officer directly owned 194,309 shares in the company, valued at approximately $23,758,161.43. This represents a 9.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 5,000 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $122.25, for a total value of $611,250.00. Following the completion of the transaction, the chief financial officer directly owned 42,181 shares of the company’s stock, valued at approximately $5,156,627.25. This trade represents a 10.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 65,315 shares of company stock worth $6,991,928. Company insiders own 8.32% of the company’s stock.

Mirum Pharmaceuticals Trading Down 4.4%

Shares of MIRM opened at $107.30 on Thursday. The stock’s 50-day moving average price is $109.68 and its 200 day moving average price is $101.18. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28. The firm has a market capitalization of $6.54 billion, a price-to-earnings ratio of -7.88 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a 12-month low of $50.25 and a 12-month high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The firm had revenue of $159.88 million during the quarter, compared to the consensus estimate of $148.21 million. During the same quarter in the prior year, the business posted ($0.30) EPS. Mirum Pharmaceuticals’s revenue was up 43.3% compared to the same quarter last year. As a group, research analysts predict that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.